ArticleMicroorganisms2026
Development and Validation of a Predictive Model for Wheezing Illness Following Human Bocavirus 1 Infection in Children.
Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Human Bocavirus 1 (HBoV1) is one major pathogen that has been associated with wheezing illnesses. However, there is still a lack of effective clinical predictive indicators for wheezing illnesses in children infected with HBoV1. A retrospective cohort study was conducted among pediatric patients with single-HBoV1 infection from September 2016 to August 2023. Then, univariate logistic regression was used to screen potential predictors for wheezing illness, and Least Absolute Shrinkage and Selection Operator (LASSO) regression was applied to minimize overfitting and select key predictors. Finally, a multivariate logistic regression model was constructed in a training dataset comprising 80% of patients and validated in an independent test dataset comprising 20% of patients. Then, its performance was evaluated using the Area Under the Curve (AUC). A total of 330 pediatric patients were enrolled, including 228 in the wheezing-illness group and 102 in the non-wheezing group. Three independent predictors, including abnormal NK cell percentage (OR = 1.101, 95 %CI 1.03-1.27), preterm birth (OR = 1.65, 95 %CI 1.49-1.82) and personal history of allergy (OR = 1.25, 95 %CI 1.11-1.41), were identified. The model achieved AUCs of 0.904 and 0.876 in the training and test sets, respectively. Using a Youden-derived threshold (0.382), the high-risk group in the test set had an observed wheezing rate of 85.3%, compared with 18.7% in the low-risk group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.